Drug guidance
Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
Condition
Eye
4 January 2022
Published on 04 Jan 2022
Last Updated on 04 Jan 2022
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Ranibizumab 1.65 mg/0.165 ml pre-filled syringe and 2.3 mg/0.23 ml solution for injection as an alternative to intravitreal bevacizumab for treating adults with visual impairment due to:
neovascular (wet) age-related macular degeneration;
diabetic macular oedema; and
macular oedema secondary to central or branch retinal vein occlusion
in view of an acceptable price proposal from the manufacturer.
Subsidy status
Ranibizumab is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.